SITC 2026 Preview: Emerging Cancer Immunotherapies and Industry Developments
SITC 2026 at a glance SITC 2026 will spotlight emerging cancer immunotherapies,…
Georgiamune and Menarini Sign $1.1B GIM-621 Licensing Deal | Lucid Diligence Brief
This Lucid Diligence Brief explores Georgiamune and Menarini’s $1.1 billion…
Oncology Strategic Roundup | July 02 – Aug 07, 2026
Oncology Strategic Roundup exploring Developments and Competitive Shifts…
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration…
Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like receptor assets
Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like…
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and Tedopi
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and…
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology…
Oncology Today—February 9, 2026
This week's Oncology update , covers regulatory actions, late-stage clinical…
Oncology Today—January 19, 2026
This week's Oncology roundup covers regulatory approvals and filings,…
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
The defining idea of 2025 was execution at scale—more patients pulled into…
ESMO Immuno-Oncology 2025 Preview: Key Highlights to Watch
ESMO Immuno-Oncology 2025 at a glance Get ready for ESMO Immuno-Oncology…
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…